Revelation Biosciences, Inc.
REVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001810560
No open-market purchases or sales by Revelation Biosciences, Inc. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $313.2K in total; no superinvestor holds it.
Other share classesREVBW
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 12
- 13F valueReported value at the end of Q2 2026
- $313.2K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding REVB, Q2 2026
No superinvestor reported holding REVB at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Revelation Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 12, 2023 (view filing) | Dec 8 | 4 days | Tidmarsh George FDirector | SSale | −27.8K | $0.52 | −$14.4K | −100.0%0 after | |
| Oct 18, 2023 (view filing) | Oct 16 | 2 days | Tidmarsh George FDirector | SSale | −1.84K | $0.65 | −$1.20K | −6.2%27.8K after | |
| Oct 17, 2023 (view filing) | Oct 16 | 1 day | Tidmarsh George FDirector | SSale | −11.0K | $0.66 | −$7.23K | −20.7%42.1K after | |
| Oct 2, 2023 (view filing) | Sep 28 | 4 days | Tidmarsh George FDirector | SSale | −1.43K | $0.69 | −$986.01 | −3.3%42.1K after | |
| Sep 18, 2023 (view filing) | Sep 14-18 | 4 days | Tidmarsh George FDirector | SSale | −25.5K | $0.741 | −$18.9K | −39.3%39.3K after | 3 lots |
| Apr 19, 2023 (view filing) | Apr 17-18 | 2 days | Tidmarsh George FDirector | PPurchase | +51.5K | $1.16 | +$59.7K | +385.8%64.8K after | 2 lots |
| Feb 28, 2022 (view filing) | Feb 25 | 3 days | Tidmarsh George FDirector, 10% Owner | PPurchase | +20.0K | $1.60 | +$32.0K | +4.5%467.2K after | |
| Feb 10, 2022 (view filing) | Feb 8-9 | 2 days | Tidmarsh George FDirector, 10% Owner | PPurchase | +31.0K | $2.55 | +$79.0K | +7.4%447.2K after | 2 lots |
| Feb 9, 2022 (view filing) | Feb 4-7 | 5 days | Tidmarsh George FDirector, 10% Owner | PPurchase | +50.0K | $2.56 | +$128.1K | +3.4%1.52M after | Amended2 lots |
| Feb 9, 2022 (view filing) | Feb 4 | 5 days | Tidmarsh George FDirector, 10% Owner | PPurchase | +2.00K | $2.45 | +$4.90K | +0.5%416.2K after | Amended |
Top 10 13F holders, Q2 2026
The largest institutional positions in Revelation Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sabby Management, LLC | 210,582 | $216.9K | 1.80% | +111,150+111.8% | Added |
| Citadel Advisors LLC | 38,579 | $39.7K | 0.00% | +38,579 | New |
| Geode Capital Management, LLC | 17,192 | $17.7K | 0.00% | −26,003−60.2% | Reduced |
| HRT Financial LP | 16,978 | $17.0K | 0.00% | +16,978 | New |
| Vanguard Fiduciary Trust Co | 13,127 | $13.5K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 6,528 | $6.72K | 0.00% | +2,454+60.2% | Added |
| Royal Bank of Canada | 747 | $1.00K | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 344 | $354 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 168 | $173 | 0.00% | +168 | New |
| Harbour Investments, Inc. | 41 | $42 | 0.00% | 00.0% | Unchanged |